For Patients

LOGICS evaluated the proportion of patients with mUFC normalization1

LOGICS had an open-label dose titration and maintenance phase for up to 19 weeks, followed by an 8-week double-blind, placebo controlled, randomized withdrawal phase and 8 weeks of double-blind restoration.1,2

Key efficacy endpoint1

The proportion of patients with mUFC normalization, defined as a patient with mUFC at or below the ULN at the end of randomized withdrawal phase without meeting a requirement for early rescue during the randomized withdrawal phase.

LOGICS evaluated the proportion of patients with mUFC normalization Dose titration and maintenance (N=79) Double-blind withdrawl (n=44) Double-blind restoration (n=43)
LOGICS evaluated the proportion of patients with mUFC normalization Dose titration and maintenance (N=79) Double-blind withdrawl (n=44) Double-blind restoration (n=43)
  • *mUFC normalization was defined as patients with mUFC at or below the ULN at the end of the withdrawal phase without requiring early rescue during the randomized withdrawal phase.1

Of those who entered the randomized withdrawal phase, significantly more patients taking Recorlev achieved mUFC normalization† vs placebo1

52% of participants (n=21) taking Recorlev achieved mUFC normalization compared with placebo 6% (n=18)
52% of participants (n=21) taking Recorlev achieved mUFC normalization compared with placebo 6% (n=18)
  • †At the end of the randomized withdrawal phase.

BID=twice daily; mUFC=mean urinary free cortisol; ULN=upper limit of normal.

References: 1. Recorlev. Prescribing Information. Xeris Pharmaceuticals, Inc; 2021. 2. Data on file. Xeris Pharmaceuticals, Inc. 2021.

Sonics Study Results >